Jennifer Vera
Investor Relations
Replay available
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) Q2 2024 earnings conference call, held 2024-05-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Jay Lulli
President and Chief Executive Officer
Paul Mellett
Chief Financial Officer
Dr. Tara Kiefer
Chief Product Strategy Officer
Eric Joseph
Analyst at JP Morgan
Thomas Yip
Q&A Participant
Dr. Scott Rottinghaus
Chief Medical Officer
Roy Buchanan
Analyst at Citizens JMP
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Enanta Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.089 -- 00:00:05.613 Good afternoon and welcome to Enanta Pharmaceuticals Fiscal Second Quarter 00:00:05.613 -- 00:00:09.817 Financial Results Conference Call. At this time, all participants are on a listen-only 00:00:09.817 -- 00:00:14.440 mode. There will be a question and answer session at the end of the prepared remarks. 00:00:14.440 -- 00:00:17.282 Please be advised that this call is being recorded. 00:00:17.282 -- 00:00:21.466 I would now like to turn the call over to Jennifer Vera, Investor Relations. 00:00:21.466 -- 00:00:23.946 Please go ahead. 00:00:26.349 -- 00:00:30.270 Thank you, Operator, and thanks to everyone for joining us this afternoon. 00:00:30.270 -- 00:00:35.934 The news release with our fiscal second quarter financial results was issued this afternoon 00:00:35.934 -- 00:00:41.318 and is available on our website. Making remarks on today's call are Dr. 00:00:41.318 -- 00:00:46.362 Jay Lulai, President and Chief Executive Officer, and Paul Mellett, our Chief 00:00:46.362 -- 00:00:51.366 Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer, 00:00:51.366 -- 00:00:56.290 and Dr. Tara Kiefer, our Chief Product Strategy Officer, will be available during the 00:00:56.290 -- 00:00:58.902 Q&A portion of the call. 00:00:58.902 -- 00:01:02.765 Before we begin with our formal remarks, we want to remind you that we will be making 00:01:02.765 -- 00:01:07.490 forward-looking statements. These statements may include our plans and expectations with 00:01:07.490 -- 00:01:11.954 respect to our research and development pipeline and financial projections. 00:01:11.954 -- 00:01:16.458 All of these statements involve certain assumptions and risks beyond our control that 00:01:16.458 -- 00:01:22.283 could cause our actual developments and ...